Anticancer agent 75

Anticancer agent 75 exhibits potent and selective cytotoxicity against cancer cell lines, alongside notable antiplasmodial activity. It demonstrates significantly reduced toxicity in normal human kidney cells compared to Doxorubicin. This profile supports its investigation in oncology and parasitology research, including in vitro mechanistic studies and in vivo efficacy models.